Category Archives: Meetings

Pharma's Promotional Spend: What's the Right Target?

Global consultancy Cegedim has released its latest survey on how and where big Pharma puts its promotional dollar. Pharmaceutical Promotional Spend: Global Trends reports that spending in emerging markets significantly increased last year, while Europe and US declined slightly.  Although overall promotion spending remained flat worldwide at $90 billion, the US still accounts for the […]
Also posted in Advertising, Emerging Markets, Europe, Global, Marketing, Sales, social media, Strategy, Technology | Tagged , , , , , | Leave a comment

Pharma in the Dell: Working with Academia

How can the emerging field of data science help to fruitfully translate research and discovery into successful drug development? Academics and pharmaceutical executives at Mount Sinai’s School of Medicine discussed ways to build a bridge across the valley of death, and the growing importance of data across all business areas.
Also posted in Biotech, Deals, IP, leadership, People, R&D, Strategy, Technology | Tagged , , , , , , | Leave a comment

Diabetes Drug Launch 2012: Tip-tops and Promo-flops

With Halloween candy flooding the shelves in pharmacies across the nation, it’s only appropriate that we turn the conversation toward an ever-growing drug market and therapeutic area: diabetes.
Also posted in Advertising, E-Media, FDA, Marketing, Strategy | Tagged , , , , , | 1 Comment

FDA, AdvaMed Seeking Clarity on Med Device Pre-Market Approvals

by Elizabeth Hollis The FDA and the Advanced Medical Technology Association (AdvaMed) gave cardiovascular device manufacturers plenty to think about over the holiday weekend with information presented at an Aug. 28 workshop. The two bodies came together to explain requirements for 30-day notices and annual change reports for Pre-Market Approvals (PMAs), an important gateway to […]
Also posted in FDA, Guest Blog, IP, Legal, Manufacturing, Market Access, Regulatory, Safety, Strategy, Technology | Tagged , | 1 Comment

Fixing Innovation: Lilly's CEO Says Why, and How

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Also posted in Europe, Events, FDA, Global, healthcare, IP, leadership, Legal, Market Access, People, pricing, R&D, Regulatory, Safety, Strategy, Technology | Tagged , , , , , , , , , , , , , | 1 Comment
  • Categories

  • Meta